The trial enrolled adults with obesity or overweight who also had established cardiovascular disease, chronic kidney disease, and/or at least two weight-related complications or risk factors. It met its primary endpoint for non-inferiority on major adverse cardiovascular events (hazard ratio 0.89). According to Zealand, survodutide is the first glucagon/GLP-1 dual agonist to complete a global cardiovascular safety trial.

Patients on survodutide lost up to 13.7% of their body weight at 72 weeks, compared with 2.0% on placebo. They also had larger reductions in systolic blood pressure and waist circumference. The results were presented at the American Heart Association’s Scientific Sessions in Chicago and published in The Lancet. Boehringer Ingelheim is moving ahead with global regulatory submissions in obesity.

“With the SYNCHRONIZE-CVOT results reported today by Boehringer Ingelheim, the registrational Phase 3 SYNCHRONIZE program for survodutide in overweight and obesity is now complete,” says David Kendall, Chief Medical Officer of Zealand Pharma.